Top Day Trader Alerts (ARNA, ARMH, BP, GENZ, GILD, FSLR, ONXX)

Photo of Jon C. Ogg
By Jon C. Ogg Updated Published
This post may contain links from our sponsors and affiliates, and Flywheel Publishing may receive compensation for actions taken through them.

Many stocks are on the move for day traders and active traders this morning.  Oddly, most are not on earnings.  Some of the top percentage movers and standout stocks are Arena Pharmaceuticals, Inc. (NASDAQ: ARNA), ARM Holdings plc (NASDAQ: ARMH), BP plc (NYSE: BP), Genzyme Corp. (NASDAQ: GENZ), Gilead Sciences, Inc. (NASDAQ: GILD), First Solar, Inc. (NASDAQ: FSLR), and ONYX Pharmaceuticals, Inc. (NASDAQ: ONXX).

Arena Pharmaceuticals, Inc. (NASDAQ: ARNA) is up almost 6.5% at $6.29 on almost 500,000 shares on positive opinion ahead of its FDA review later this year.

ARM Holdings plc (NASDAQ: ARMH) is up another 2.7% at $16.59 on follow-on buying after Friday’s Microsoft license.

BP plc (NYSE: BP) is up almost 3% after Bonnie fizzled and did not hurt the BP cap but most importantly the stock is up on word that Tony Hayward is just about to be tossed out as CEO.  ADRS are up 2.95% at $37.95 on almost 750,000 shares.

Genzyme Corp. (NASDAQ: GENZ) is up another 6% at $66.50 on very active pre-market trading on worth that J&J and/or GlaxoSmithkline may be interested in the company as well.  Sanofi-Aventis was the front runner on Friday that put shares at a 52-week high. Other Peers Noted as Possible Candidates as well.

Gilead Sciences, Inc. (NASDAQ: GILD) is down slightly after announcing it will offer $2.2 billion worth of convertible senior notes and that it will use at least $1 billion of the proceeds to repurchase common stock.  Shares were up originally but the stock is now flat.

First Solar, Inc. (NASDAQ: FSLR) might have been worse on a different morning.  Barron’s panned the issue over safety issues and margin issues on sales where prices keep drifting lower.

ONYX Pharmaceuticals, Inc. (NASDAQ: ONXX) is one of the top percentage movers after announcing positive top-line Carfilzomib data from a Phase IIb study in blood cancer.  Shares are up 12% at $24.17 on over 700,000 shares.

You can join our free daily email distribution list to hear more about dividend trends, analyst upgrades and downgrades, top day trader and active trader alerts, news on Buffett and other investment gurus, IPOs, secondary offerings, private equity, and more.

JON C. OGG

Photo of Jon C. Ogg
About the Author Jon C. Ogg →

Jon Ogg has been a financial news analyst since 1997. Mr. Ogg set up one of the first audio squawk box services for traders called TTN, which he sold in 2003. He has previously worked as a licensed broker to some of the top U.S. and E.U. financial institutions, managed capital, and has raised private capital at the seed and venture stage. He has lived in Copenhagen, Denmark, as well as New York and Chicago, and he now lives in Houston, Texas. Jon received a Bachelor of Business Administration in finance at University of Houston in 1992. a673b.bigscoots-temp.com.

Featured Reads

Our top personal finance-related articles today. Your wallet will thank you later.

Continue Reading

Top Gaining Stocks

CBOE Vol: 1,568,143
PSKY Vol: 12,285,993
STX Vol: 7,378,346
ORCL Vol: 26,317,675
DDOG Vol: 6,247,779

Top Losing Stocks

LKQ
LKQ Vol: 4,367,433
CLX Vol: 13,260,523
SYK Vol: 4,519,455
MHK Vol: 1,859,865
AMGN Vol: 3,818,618